Chaidos Lab

Contact

Dr Aristeidis Chaidos

  • Consultant haematologist and honorary senior lecturer at the Hammersmith Hospital and Imperial College London
  • Expertise in multiple myeloma, lymphoma, and stem cell transplantation

+44 (0)20 3313 4017
a.chaidos@imperial.ac.uk

Areas of research

Myeloma functional heterogeneity in clinical drug resistance and residual disease

Myeloma heterogeneity is the single most important obstacle for optimal therapeutic targeting. A complex genetic landscape, epigenetic mechanisms and cues from tumour microenvironments shape the phenotypic and functional diversification of myeloma cells, which underpins drug resistance and later relapsed disease. Differential transcriptional profiles and gene expression regulatory mechanisms at diagnosis and residual disease provide insight into the biology of drug resistance and reveal novel disease vulnerabilities.

The lab is particularly interested in the biology of BCL2 family proteins. BCL2 inhibition is a promising targeted therapy for t(11;14) myeloma and a unique paradigm of treatment directed by genetics.

Myeloma kidney disease and MGRS

Myeloma kidney disease is a debilitating complication with a profound impact on treatment outcome and survival. Monoclonal Gammopathy of Renal Significance (MGRS) is a rare disease, where small amounts of highly nephrotoxic immunoglobulins or free light chains, produced by otherwise subclinical plasma cell clones, resulting in a bewildering array of renal histopathology and kidney disease.

The lab collaborates with Renal Medicine and Histopathology at Imperial to establish experimental vitro and vivo models of myeloma cast nephropathy and MGRS. We study the proinflammatory and profibrotic pathways induced by the nephrotoxic immunoglobulins and develop novel diagnostics and therapeutic strategies.

Citation

BibTex format

@article{Kousios:2019:10.1016/j.ekir.2019.02.003,
author = {Kousios, A and Storey, R and Troy-Barnes, E and Hamady, M and Salisbury, E and Duncan, N and Charif, R and Tam, F and Cook, T and Crane, J and Chaidos, A and Roufosse, C and Flora, R},
doi = {10.1016/j.ekir.2019.02.003},
journal = {Kidney International Reports},
pages = {749--755},
title = {Plasmacytoma-like post-transplant lymphoproliferative disease in a disused arterio-venous fistula: the importance of histopathology.},
url = {http://dx.doi.org/10.1016/j.ekir.2019.02.003},
volume = {4},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Common causes of swelling in arteriovenous fistulae (AVFs) include thrombosis, infection, aneurysm, and superior vena cava (SVC) obstruction secondary to previous dialysis vascular catheter use. Malignancies confined in AVFs are rare and have been described in case series and case reports, mostly in immunosuppressed patients.1 Patients who undergo transplantation frequently have functioning or nonfunctioning AVFs. The risk of malignancy is increased in this patient group and thus should be considered in patients presenting with symptomatic AVF. The most common histopathological diagnosis is angiosarcoma.1, 2 Plasmacytoma-like posttransplant lymphoproliferative disease (PTLD) confined in an AVF has not been previously described.
AU  - Kousios,A
AU  - Storey,R
AU  - Troy-Barnes,E
AU  - Hamady,M
AU  - Salisbury,E
AU  - Duncan,N
AU  - Charif,R
AU  - Tam,F
AU  - Cook,T
AU  - Crane,J
AU  - Chaidos,A
AU  - Roufosse,C
AU  - Flora,R
DO  - 10.1016/j.ekir.2019.02.003
EP  - 755
PY  - 2019///
SN  - 2468-0249
SP  - 749
TI  - Plasmacytoma-like post-transplant lymphoproliferative disease in a disused arterio-venous fistula: the importance of histopathology.
T2  - Kidney International Reports
UR  - http://dx.doi.org/10.1016/j.ekir.2019.02.003
UR  - https://www.sciencedirect.com/science/article/pii/S2468024919300452?via%3Dihub
UR  - http://hdl.handle.net/10044/1/67411
VL  - 4
ER  -
Download